OBIZUR
Biological
Takeda Pharmaceuticals U.S.A., Inc.
Total Payments
$12.7M
Transactions
684
Doctors
123
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.7M | 5 | 1 |
| 2023 | $1.4M | 3 | 0 |
| 2022 | $1.7M | 27 | 4 |
| 2021 | $1.8M | 41 | 13 |
| 2020 | $1.5M | 84 | 11 |
| 2019 | $2.1M | 103 | 28 |
| 2018 | $1.5M | 163 | 50 |
| 2017 | $1.1M | 258 | 34 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $12.1M | 30 | 94.6% |
| Unspecified | $495,972 | 330 | 3.9% |
| Travel and Lodging | $60,520 | 94 | 0.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,256 | 29 | 0.5% |
| Consulting Fee | $59,919 | 41 | 0.5% |
| Food and Beverage | $5,198 | 158 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $2,000 | 1 | 0.0% |
| Education | $37.65 | 1 | 0.0% |
Payments by Type
General
$12.2M
354 transactions
Research
$495,972
330 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| POST-MARKETING NON-INTERVENTIONAL SAFETY EVALUATION OF OBIZUR IN THE TREATMENT OF BLEEDING EPISODES FOR PATIENTS WITH ACQUIRED HEMOPHILIA A | Shire North American Group Inc | $211,491 | 0 |
| PROSPECTIVE AND RETROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF OBIZUR IN REAL-LIFE PRACTICE | Takeda Pharmaceuticals U.S.A., Inc. | $108,594 | 0 |
| THE COST-EFFECTIVENESS OF OBI-1 FOR TREATMENT OF ACQUIRED HEMOPHILIA A ANALYSIS OF CLINICAL TRIAL AND RELATED DATA | Shire North American Group Inc | $86,938 | 0 |
| POST-MARKETING NON-INTERVENTIONAL SAFETY EVALUATION OF OBIZUR IN THE TREATMENT OF BLEEDING EPISODES FOR PATIENTS WITH ACQUIRED HEMOPHILIA A | Takeda Pharmaceuticals U.S.A., Inc. | $81,708 | 0 |
| A PHASE 3, MULTICENTER, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF B-DOMAIN DELETED RECOMBINANT PORCINE FACTOR VIII BAX 802 IN SUBJECTS WITH CONGENITAL HEMOPHILIA A WITH FACTOR VIII INHIBITORS UNDERGOING SURGICAL OR OTHER INVASIVE PROCEDURES | Shire North American Group Inc | $7,241 | 0 |
Top Doctors Receiving Payments for OBIZUR — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Emergency Medicine | San Juan, PR | $15.95 | 1 |
| , M.D | General Practice | San Juan, PR | $15.95 | 1 |
| , MD, FACEP | Emergency Medicine | San Juan, PR | $15.95 | 1 |
| , MD | General Practice | San Juan, PR | $15.95 | 1 |
| Nelson Robles Cardona | — | Aibonito, PR | $15.95 | 1 |
| , M.D | General Practice | San Juan, PR | $15.95 | 1 |
| , MD | Personal Emergency Response Attendant | Guaynabo, PR | $15.95 | 1 |
| , M.D | General Practice | San Juan, PR | $15.95 | 1 |
| , MD | Hematology & Oncology | Homestead, FL | $15.95 | 1 |
| , M.D | Emergency Medical Services | Yauco, PR | $15.95 | 1 |
| , M.D | Emergency Medicine | San Juan, PR | $15.95 | 1 |
| , MD | Hematology & Oncology | San Juan, PR | $14.92 | 1 |
| , M.D | Urology | San Juan, PR | $14.92 | 1 |
| , M.D | Surgery | San Juan, PR | $14.92 | 1 |
| , MD | Undersea and Hyperbaric Medicine | Bernville, PA | $14.01 | 1 |
| Tamna Wangjam | Internal Medicine | Baltimore, MD | $13.76 | 1 |
| , M.D | Hematology & Oncology | San Antonio, TX | $13.76 | 1 |
| , M.D | Hematology & Oncology | San Francisco, CA | $13.76 | 1 |
| , MD | Hematology & Oncology | San Antonio, TX | $13.76 | 1 |
| , MD | Hematology & Oncology | San Juan, PR | $13.67 | 1 |
| , M.D | Oncology | Rio Piedras, PR | $13.29 | 1 |
| , MD | Internal Medicine | San Juan, PR | $13.29 | 1 |
| , M.D | Hematology & Oncology | San Juan, PR | $10.95 | 1 |
| , M.D | Pediatrics | Chicago, IL | $3.31 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $12.7M
- Total Doctors 123
- Transactions 684
About OBIZUR
OBIZUR is a biological associated with $12.7M in payments to 123 healthcare providers, recorded across 684 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2017 to 2024. In 2024, $1.7M was paid across 5 transactions to 1 doctors.
The most common payment nature for OBIZUR is "Royalty or License" ($12.1M, 94.6% of total).
OBIZUR is associated with 5 research studies, including "POST-MARKETING NON-INTERVENTIONAL SAFETY EVALUATION OF OBIZUR IN THE TREATMENT OF BLEEDING EPISODES FOR PATIENTS WITH ACQUIRED HEMOPHILIA A" ($211,491).